Products - Autoimmune - Nephrology - Primary membranous nephropathy

Primary membranous nephropathy

Contact our Autoimmune Product Team for further details and information

Information

Membranous nephropathy is a chronic inflammatory disease of the glomeruli accompanied by progressive impairment of the kidney function.

Diagnostic Guidelines

A distinction is made between the primary form (pMN), which has an autoimmune origin and accounts for about 70% to 80% of cases, and the secondary form (sMN), which develops from an underlying disease such as an infection, from the use of medication, drugs or toxins or from another autoimmune disease or cancer. The onset of pMN is gradual and varies from patient to patient. About one-third of patients experience spontaneous remission, one-third continue to suffer from proteinuria with stable renal function, and another third progress to end-stage renal disease (ESRD).

It is the most frequent cause of nephrotic syndrome in adults.

Autoantibodies against phospholipase A2 receptor (PLA2R) and thrombospondin type 1 domain-containing protein 7A (THSD7A) are characteristic of pMN. Anti-PLA2R antibodies occur in pMN with a prevalence of 70% to 80%, while anti-THSD7A antibodies can be found in 3% to 5% of patients. Anti-THSD7A antibodies are predominantly detected in anti-PLA2R-negative patients and therefore play a complementary role in serodiagnosis. The specificity of both antibodies for pMN is very high. For a long time, kidney biopsy was considered the gold standard for diagnosing pMN. However, according to the current KDIGO guideline, pMN can be diagnosed in nephrotic patients with positive anti-PLA2R antibody results without performing an additional biopsy. Only in the case of anti-PLA2R-negative results or in patients with impaired renal function who are receiving immunosuppressive therapy should a biopsy still be considered, as the antibody titer may be reduced by the treatment. Anti-PLA2R antibodies also correlate with the clinical activity of the disease. With successful immunosuppressive therapy, the titer drops within a short time. The determination of the antibody titer is therefore a suitable tool for monitoring the disease status and the patient’s response to therapy.

pMN-associated autoantibodies can be determined with test systems exclusively available from EUROIMMUN. The indirect immunofluorescence test (IIFT) enables the qualitative and semi-quantitative detection of anti-PLA2R and anti-THSD7A antibodies, respectively, using transfected cells that express the corresponding antigen on their surface. However, anti-PLA2R antibodies can also be measured quantitatively by ELISA or chemiluminescence immunoassay (ChLIA). In ELISA, the recombinant PLA2R antigen is applied to the wells of a microplate, while ChLIA uses magnetic particles coated with the antigen. Quantitative antibody measurement is ideal for disease and therapy monitoring and can be performed efficiently with high throughput thanks to state-of-the-art automation solutions.

For more information, literature and lectures on PLA2R as a serological marker of pMN, see pla2r.com

Primary membranous nephropathy products

For Research Use Only. Not For Use In Diagnostic Procedures.
The individual product regulatory statements may vary, please refer to the instructions for use for more information.

wdt_ID Method Parameter Substrate Species/ Antigen
708 IFA antibodies against phospholipase A2 receptor
(PLA2R ab control)
709 ELISA phospholipase A2 receptor
(PLA2R)
antigen-coated
microplate wells
recombinant, human c-DNA
expressed in human cell line
710 ChLIA control set
phospholipase A2 receptor
(PLA2R)
711 ChLIA phospholipase A2 receptor
(PLA2R)
712 IFA antibodies against thrombospondin type-1 domain-containing protein 7A
(THSD7A ab control)
713 IFA Membranous Nephropathy Mosaic 1
phospholipase A2 receptor (PLA2R)
Thrombospondin type-1 domain-containing
protein 7A (THSD7A)
3 BIOCHIPs per field:
transfected cells
transfected cells
control transfection
EU 90
EU 90
EU 90
714 IFA phospholipase A2 receptor (PLA2R) transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
715 IFA phospholipase A2 receptor (PLA2R)
EUROPattern
transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
716 IFA Thrombospondin type-1 domain-
containing protein 7A (THSD7A)
transfected cells
control transfection
(2 BIOCHIPs per field)
EU 90
EU 90
717
Method Parameter Substrate Species/ Antigen
table.wpDataTable { table-layout: fixed !important; } table.wpDataTable td, table.wpDataTable th { white-space: normal !important; } /* buttons background color */ .wpDataTables .wdt-checkbox-filter.btn, .wdt-frontend-modal .btn, div.dt-button-collection a.dt-button.active:not(.disabled), div.dt-button-collection button.dt-button.active:not(.disabled) { background-color: #3eb44a !important; background-image: none !important; } /* buttons border color */ .wpDataTables .wdt-checkbox-filter.btn, .wdt-frontend-modal .btn:not(.dropdown-toggle), div.dt-button-collection a.dt-button.active:not(.disabled), div.dt-button-collection button.dt-button.active:not(.disabled) { border: 1px solid; border-color: #ffffff !important; } /* buttons font color */ .wpDataTables .wdt-checkbox-filter.btn, .wpDataTables .selecter .selecter-selected, .wdt-frontend-modal .btn:not(.dropdown-toggle), div.dt-button-collection a.dt-button.active:not(.disabled), div.dt-button-collection button.dt-button.active:not(.disabled) { color: #ffffff !important; } /** buttons background hover color */ .wpDataTables .wdt-checkbox-filter.btn:hover, .wdt-frontend-modal .btn:not(.dropdown-toggle).btn:hover, div.dt-button-collection a.dt-button.active:not(.disabled):hover, div.dt-button-collection button.dt-button.active:not(.disabled):hover { background-color: #ffffff !important; background-image: none !important; } /** buttons hover border color */ .wpDataTables .wdt-checkbox-filter.btn:hover, .wdt-frontend-modal .btn:not(.dropdown-toggle).btn:hover, div.dt-button-collection a.dt-button.active:not(.disabled):hover, div.dt-button-collection button.dt-button.active:not(.disabled):hover { border-color: #3eb44a !important; } /** buttons hover font color */ .wpDataTables .wdt-checkbox-filter.btn:hover, .wdt-frontend-modal .btn:not(.dropdown-toggle).btn:hover, div.dt-button-collection a.dt-button.active:not(.disabled):hover, div.dt-button-collection button.dt-button.active:not(.disabled):hover { color: #3eb44a !important; } /** buttons hover font color */ .wpDataTables .wdt-checkbox-filter.btn:hover, .wdt-frontend-modal .btn:not(.dropdown-toggle).btn:hover, div.dt-button-collection a.dt-button.active:not(.disabled):hover { color: #3eb44a !important; } /* table font size */ .wpdt-c.wpDataTablesWrapper table.wpdtSimpleTable, .wpdt-c .wpDataTablesWrapper table.wpDataTable { font-size:17px !important; }
Contact our Autoimmune Product Team for further details and information
Download Our Latest <br/>EUROIMMUN US Product Catalog

Product Catalog

Download Our Latest
EUROIMMUN US Product Catalog

Download The EUROIMMUN US Product Catalog (PDF)

2024 EUROIMMUN US

Privacy Policy | Sitemap